dc.contributor.author |
Hunt, Michelle |
en |
dc.contributor.author |
Li, D |
en |
dc.contributor.author |
Hay, Michael |
en |
dc.contributor.author |
Currie, MJ |
en |
dc.contributor.author |
Robinson, BA |
en |
dc.contributor.author |
Patterson, Adam |
en |
dc.contributor.author |
Dachs, GU |
en |
dc.date.accessioned |
2012-01-23T01:41:12Z |
en |
dc.date.issued |
2012 |
en |
dc.identifier.citation |
Journal of Gene Medicine 14(1):62-74 2011 |
en |
dc.identifier.issn |
1099-498X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/10643 |
en |
dc.description.abstract |
Background Enzyme prodrug gene therapy is designed as a targeted cancer treatment, destroying gene-modified and bystander cells via exogenous enzyme-generated cytotoxins. Targeting of tumour blood vessels using gene therapy is attractive, although optimal enzyme prodrug combinations have yet to be identified. Methods Seven enzyme prodrug combinations were ranked in two endothelial (HUVEC, HMEC-1) and one tumour cell line (T24) for their ability to reduce proliferation and viability. The ability to destroy bystander cells in two dimensions (2D) and three dimensions (3D), mode of cell kill, and the ability to disrupt vascular networks were measured. Results Endothelial cell proliferation (bromodeoxyuridine uptake) was reduced most effectively by Herpes simplex virus thymidine kinase (TK) with ganciclovir (GCV), followed by Escherichia coli nitroreductase NfsB (NTR) with CB1954; viability [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay] was reduced most efficiently by NTR/CB1954 followed by TK/GCV. Of the seven combinations, only NTR/CB1954 displayed measurable bystander effects in 2D monolayers, and none demonstrated bystander killing in coated spheroids, a 3D spatially distinct model with tissue-like cell density. NTR-expressing endothelial cells displayed increased apoptosis, necrosis and caspase-3 activity after CB1954 treatment. Despite good antiproliferative activity, TK/GCV was ineffective at disrupting vascular network-like structures of endothelial cells, whereas NTR/CB1954 was efficient. NTR/metronidazole and the vascular disrupting agent, combretastatin A-4 phosphate, were the only other effective agents. Conclusions Collectively, these data demonstrate that cytotoxic rather than cytostatic activity is necessary for efficient vascular disruption in vitro, and bystander killing is not essential. We identify NTR/CB1954 and NTR/metronidazole as candidates for in vivo investigation of vascular-targeted gene therapy. |
en |
dc.publisher |
John Wiley & Sons, Ltd. |
en |
dc.relation.ispartofseries |
Journal of Gene Medicine |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1099-498X/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1002/jgm.1635 |
en |
pubs.issue |
1 |
en |
pubs.begin-page |
62 |
en |
pubs.volume |
14 |
en |
dc.rights.holder |
Copyright: 2012 John Wiley & Sons, Ltd. |
en |
dc.identifier.pmid |
22147660 |
en |
pubs.end-page |
74 |
en |
pubs.publication-status |
Accepted |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
277385 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2012-01-23 |
en |
pubs.dimensions-id |
22147660 |
en |